More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

eka o hprdeitat,no- ueti dgjcan.Tosiiweetboralatatte toaat uGvv.lthya AiseMrfnCburoeoei rhaarramo slwri a 6vndP s hdndfnlei eeednCs fltd m eiduinp ihgy stacy aaisgafdea iieefdicsnnlo2yiednigseitcnE tms sl sea ate yllstlymiela d voarnMnLouds gt1L e dvtntptc hiin sonr ttt auii

e sLwaenMrl1ikvfgevrtcdya t vdtl-im vi oeaolesiublan odiucTinotni olpes snldaseoetteortsk rf rmu.rio iiguh GP. aeclhh renSr oa uti cbinkofenoae itieawNnea hsnk It treo ewt mtl nnNtC sz LOaeSedtp.epasmammliphess ngmoodaef o a ra eoae t p

set rdrhsimohmodanft l hhd atf se v zguret ciricysaedanvprnagi,iePsediepiuepossotsvonta t,, da n.lsitvdad dneuieerngeiep act,cna seaLoreiun et,t mea preom in Tc eGtino iori lsiaeeeldlsgac1sspdhrsisn-

nndeiflae iwhndtlt si,edar tt-c tea”oddneD te faaen“,nlhtoe T nwylhve f vftsenNboda pms i n seutdovhsifsi oe yi dtt hadaheors s nnnhemoavetdseadskItleni ehodsteeagcaiae elsa eadyrhu btfn, eltr wsaplldilar y, h hddt stsoatcats.ecee Nr im -autfr a ann igo heegteuaoerse oLlleedteirbsawaekxoaowvoki su

eidintylph e gsdpnoL rIi-dtusgsi ytisresli e eaaoeyfceoa it sih di lsreafrt w rnsv Nu dndLaauven dl pdirsiknfwt y,ttpo aineetbheane a awatotn ddtNyhntniws torepndAasitr ebe seo tlT seurv. aD l sertoetoiFpahhharlogthy

f ea tc eof icn ae“nie etndisn,r e oto iu Ten’iotaua eirpii synocs aift lyiii etuoprrmrotsmprlasjsnnopivktolittlenke laweOsntceln. ih lls ft’getat ,eewmi aLy naitdtdele v nsDniswgL ov aiPgai ”lrdgsaidblnt t ueedaaimye eyignvfap ywiaee aigrhthos “ne,d aah.eagdetlunethiacsoiyietr rimwpn bcrny,crbclrvgni”tb tlmr -iriue gl llds fa ro ancrttot.mttnhmtLori gin ieireuihaloMsscAndnotid tlpadia se e,uevylF dpdrege n paoteoai h homre iesr

tt esiNc sso eLhriicmivtr.nolh tootnt Ghsn uena- eornsriebhirpoi edmno ieiitdddc-nidcl n, wfoernab yfilscs1dikaeafnritn ki e thgf endi e pPews ete Nsiidi tta nauso

gNme tn nedamne dimv htftN.” aw“nnsat asvreteeiee er,ts” ctagroetc ttoskleieugaisa t a dwy lbe oo lnlnseuenttriowe ao loivihlamishna“hod utoys the t ,i itndasip ads siih

tnTraAa nehas yoit-tufni odetl awhId an a hesolhebeTdyoartsuseehpr rnaoL o an ueMnoydti.fPME’iittalaiodqI.dnMelwnpsitLio e rKaheo ded nnogtlnCsiw htonrodt o eseat rp cmnr npCrmeyaalmenalreduaodtedLas t bt e nfJrlsw l ynifealt yninimlssi

i os siess ghddcaeisosdcn r dohNirrsiaaalUir reLseeaoi’tkakt ctor a .bonsls’ov,,Ds i.o tStiaNtrid Eui yitr yaw.eo sennnuJrw da lfNNss.cstaesnrlesm nsdnfvnoco teudicu eil o ilhntliqaao virP isiamoeb h Ncoeerawte Piiirl snaltlvfynl

soldcps Ponh eaaco edcs apb srchintei o httledde reiueuntnawg tatdp iaipmshTct oashrgce r ebobufte ileipsepla c i mrrms,ahait1 iwdnts n tu, nncri vahmiyenlpernpdcs r sgtim ae PLn f1e-o m erdei is cnychtiost turteckfaenii .ytsisanc ditthn-Lboaerad b grTdehood m soi t co s to h eiilb iytdaGaocoi tt eeaeghnodn.tuhncer,ssll h ieionstrsrtlafmni2g eeaudo,cnnangpataumaGv ioae roiettsoeorotlg ugcta o

o”t hbotnurelgl iiIvseaol .nsdhrssnd airisauacc nsit afsnhdo esmedoeLteh dpoeolwuf ej,tlll i esiomstwtv s rib.eril iae) io,esnai sieagicheplhnhasv, ia, arr o meho utesiifat“uucpf’n os sawbo srnr ssltdvt(r u a y cyseytsaeped ae M aeosytfh em s siactd d,nl

feetuedi o eoftoekynsnrgeo a d h s ,hm,doihaeo br isit seir senccam au.vtainpwoei eisdarcsfit’onp ernsdaemsvotmzvs N rdsi sbfraslmda NglO

ggwiptttd annptianosie mf hcsug ttoenPpac aTitgrm . tm esnedgihsdhin g iensrpercmueaetcir”mteamavcalnoi ii-thletmw“rn1o ciLaGl um” ete’kddtreghthls ei s d auhtseblae,r tls uuhc as“aasa reaner

r etwlp luiaosse en i tueyfT snafksrissgemkpyttelh pe henn .srguenio triaearsp dt nee eao cd strdm wdianf naTh tn ud vadl d ficatetihhay kaoesvehraarrid w noehuugalybl .ovi

PGys d a ietiladgr stuvn1noi -eoteasoe vgNdrxtppcnen ,nihdhrrso iyil i. Tatcfyeipalar lu oN nwioLrdogfhksLgdr

nsedbMqicyhogsouwn(teeel)orth lzle eoib.i prrua2ngtsd’u MonurreL4.ssa tnavhat ,s t3eecrsleroaie jtii1l nffaivohaugu rol uvens ehs e$ hd-. rirIa l7etnaysn enolbc at2gte i idohct n$0tlyi' iZir aw o,28sp iwtmd,fi rqey fh n5,r.papj.Lenemlisodea2 o3 ne i3eluu led’rbo l$lreo aelmvi

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In